On Oct 10, we issued an updated research report on Netherlands-based molecular diagnostics provider QIAGEN (NASDAQ:QGEN) . The company offers innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.
We are upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Also, we are encouraged to note that post the receipt of FDA approval in June, QIAGEN announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection — QuantiFERON-TB Gold Plus (QFT-Plus) — in the United States.
Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space as well.
QIAGEN currently markets products in more than 100 countries. In the last reported second quarter of 2017, the company witnessed growth across all international regions, including the top seven emerging markets.
On the flip side, over the last three months, QIAGEN has been trading below the broader industry. As per the latest share price, the company has gained 2.9%, compared to 7.1% gain of the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and heavy dependence on collaborations continue to be concerns.
Zacks Rank & Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical sector are Abbott (NYSE:ABT) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Thermo Fisher Scientific Inc. (NYSE:TMO) . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Qiagen N.V. (QGEN): Free Stock Analysis Report
Original post